[Form 4] Theravance Biopharma, Inc. Insider Trading Activity
This Form 4 filing details insider trading activity for Theravance Biopharma, Inc. (TBPH) related to a merger where the company became a wholly-owned subsidiary of Zymeworks Inc. Insider Weiss Asset Management LP disposed of over 7.4 million shares at $17.00 per share, which were converted into cash and contingent value rights. This transaction reflects the company's acquisition by Zymeworks, where shareholders received cash and CVRs for their shares.
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks (NASDAQ: ZYME) finalized its acquisition of Theravance Biopharma, updating its 2026 financial guidance. The biotechnology company projects revenue between $278 million and $292 million and adjusted EBITDA of $114 million to $128 million, anticipating immediate recurring cash flow and expanded operating leverage. The deal adds YUPELRI to its portfolio, providing a 35% share of net U.S. profits and overseas royalties, alongside potential future milestone payments and a strong financial structure with non-dilutive financing.
Theravance Biopharma: Acquisition brings YUPELRI and R&D assets, diversifying revenue and enabling future growth
Theravance Biopharma (0TB) has announced an acquisition that incorporates YUPELRI and a robust R&D portfolio, aiming to diversify revenue and strengthen its financial standing. The deal, financed by a $350M non-recourse note, targets a mid-teen internal rate of return, anticipating significant benefits from tax attributes and future R&D opportunities. This move is expected to enable future growth for the company.
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Zymeworks Inc. has announced updated 2026 financial guidance and the final transaction details after completing its acquisition of Theravance Biopharma. The acquisition adds YUPELRI® to Zymeworks' portfolio, providing a durable cash flow source, and is expected to contribute immediately accretive revenue and cash flow. The company projects total revenue for 2026 to be between $278 million and $292 million and Adjusted EBITDA between $114 million and $128 million.
Theravance Biopharma (TBPH) shares were canceled on September 23 after its Zymeworks merger.
This article reports on a SCHEDULE 13D/A SEC filing by four entities (Weiss Asset Management, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss) for Theravance Biopharma (TBPH), indicating zero beneficial ownership of TBPH shares. The filing states that TBPH shares were canceled on September 23, 2026, following its merger with Zymeworks Inc. The reporting persons did not engage in any transactions of TBPH shares within the preceding 60 days.
A director's shares became rights to $17 each plus a contingent payment in Theravance Biopharma's (TBPH) merger.
Theravance Biopharma director Donal O'Connor's 74,204 ordinary shares were converted into cash rights of $17.00 per share and one contingent value right (CVR) as part of the company's merger with Zymeworks Inc. Additionally, 6,009 shares underlying RSU awards and certain share options were also converted into cash and CVRs, while options with exercise prices at or above $17.00 were canceled without consideration. This information was reported in a Form 4 SEC filing detailing the disposition of his holdings.
Zymeworks now owns Theravance Biopharma (TBPH). A director's shares were canceled for cash and milestone rights.
Theravance Biopharma director Susannah Gray's shares and equity awards were canceled following the company's acquisition by Zymeworks Inc. on September 23, 2026. She received $17.00 cash per ordinary share and restricted stock unit, plus one non-tradeable contingent value right (CVR) per share. Her stock options were converted into cash equal to the excess of $17.00 over the exercise price, plus one CVR per share.
A 150,000-share insider option was cancelled without payment in Theravance Biopharma (TBPH)'s merger.
In the recent merger of Theravance Biopharma (TBPH) with Zymeworks Inc., an insider's 150,000-share stock option with an exercise price of $25.64 was cancelled without consideration because it exceeded the per-share cash consideration of $17.00. Additionally, the insider, Rhonda Farnum, had 124,414 ordinary shares and 89,062 restricted stock units converted into $17.00 cash per share plus one non-tradeable contingent value right (CVR) per share. The merger made Theravance Biopharma a wholly owned subsidiary of Zymeworks Inc.
A $17-a-share merger payout left an executive’s options without payment at Theravance Biopharma (TBPH).
Theravance Biopharma (TBPH) became a wholly owned subsidiary of Zymeworks Inc. on September 23, 2026, following a merger where shareholders received $17 cash and one non-tradeable contingent value right (CVR) per ordinary share. Aine Miller, SVP, DEV & HEAD OF IRE OFFICE, reported that her 37,500 stock options with an exercise price of $25.42 were canceled without consideration because the exercise price exceeded the $17 cash merger consideration. This highlights how executive options can be left valueless in mergers if their strike price is higher than the per-share acquisition price.
Theravance Biopharma CEO's 1.38M shares canceled
Theravance Biopharma (TBPH) CEO Rick E. Winningham reported the cancellation of 1,382,272 directly held ordinary shares, 23,400 custodian-held, and 92,567 trust-held shares, along with 515,000 options and various restricted stock units, following the company's merger with Zymeworks Inc. on September 23, 2026. Each share was converted into $17.00 cash and one contingent value right (CVR). The merger terms outline how different types of equity holdings were converted into cash and CVRs, with options receiving cash for the excess of $17.00 over their exercise price.
Theravance Biopharma, Inc. Announces Resignation of Rick E Winningham from Chief Executive Officer, Effective September 23, 2026
Theravance Biopharma, Inc. announced the resignation of Rick E. Winningham as Chief Executive Officer, effective September 23, 2026. This resignation is in connection with the completion of a merger, as outlined in the Merger Agreement. The company is primarily focused on developing and commercializing medicines for specialty respiratory and neurologic diseases.
Theravance Biopharma (Nasdaq: TBPH) is named in a notice to remove its shares from Nasdaq.
Nasdaq Stock Market LLC has issued a notice to remove Theravance Biopharma, Inc.'s ordinary shares from listing and registration. The filing indicates that Nasdaq has complied with its rules to strike the class of securities and that the issuer met the requirements for voluntary withdrawal. This action is documented in a Form 25 filing with the SEC.
Theravance Biopharma Announced Transfer or Voluntary Withdrawal of Listing
Theravance Biopharma (TBPH) has announced its intention to delist from Nasdaq and terminate its registration with the SEC. This decision follows a merger closing on September 23, 2026, and the company plans to file a Form 15 to suspend its reporting obligations after the delisting becomes effective.
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc. has completed its previously announced acquisition of Theravance Biopharma, integrating the company to further its strategy of becoming a diversified revenue-generating biotechnology company. This move combines innovative R&D with growing commercial and royalty-based cash flows. Zymeworks will host a conference call on September 28 to discuss the final transaction details.
Theravance Biopharma, Inc.(NasdaqGM: TBPH) dropped from S&P TMI Index
Theravance Biopharma, Inc. (NasdaqGM:TBPH) has been removed from the S&P Total Market Index (TMI). This announcement was published on September 22, 2026, at 09:08 pm EDT. The company also dropped from the S&P Global BMI Index and S&P Pharmaceuticals Select Industry Index.
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Value-Dynamic Index
Theravance Biopharma, Inc. (NasdaqGM: TBPH) has been removed from the Russell 2000 Value-Dynamic Index. This comes amidst a series of index removals for the company, including from the S&P Global BMI Index, NASDAQ Composite Index, and others, following recent corporate changes such as the acquisition by Zymeworks and the resignation of its CEO. The company, focused on respiratory and neurologic diseases, is experiencing significant shifts in its market presence.
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc.
Theravance Biopharma shareholders have approved the merger agreement with Zymeworks Inc. during an extraordinary general meeting on September 18, 2026. The Merger Proposal received overwhelming support, satisfying the supermajority condition required for closing. The merger is now anticipated to be completed on or about September 23, 2026, subject to the fulfillment of remaining conditions.
Form 8K Theravance Biopharma Inc For: 18 September By Investing.com
This article announces the filing of a Form 8K by Theravance Biopharma Inc. on September 18. It is a brief, one-line report from Investing.com, providing basic information about the regulatory filing.
Theravance Biopharma shareholders approve merger with Zymeworks
Theravance Biopharma shareholders have approved the company's merger with Zymeworks Inc. The merger will make Theravance Biopharma a wholly-owned subsidiary of Zymeworks. Shareholders will receive $17.00 per share in cash and a contingent value right for future proceeds from ampreloxetine.
Theravance Biopharma SVP Farnum Rhonda Sells 13,314 Shares at $17.03 Each
Farnum Rhonda, SVP of Communications and Medical Affairs at Theravance Biopharma, sold a total of 13,314 shares at $17.03 each across three transactions on September 15, 2026. This sale reduced her holdings by approximately 5.9%, leaving her with 213,476 shares after the transactions. The disposals were all recorded under code S.
Pre-arranged stock sale at Theravance Biopharma (TBPH)
Rhonda Farnum, Senior Vice President of Commercial and Medical Affairs at Theravance Biopharma, Inc. (TBPH), sold 13,314 ordinary shares on September 15, 2026. The sales were executed in multiple transactions at a weighted average price of approximately $17.03 per share, under a pre-arranged Rule 10b5-1 trading plan established on September 3, 2025. Following these transactions, Farnum directly holds 213,476 ordinary shares.
Theravance Biopharma SVP Rhonda Farnum sells $226k in stock
Rhonda Farnum, SVP of Communications & Medical Affairs at Theravance Biopharma (NASDAQ: TBPH), sold 13,314 shares totaling $226,793 on September 15, 2026, via a pre-arranged trading plan. This insider sale occurred as the company's stock trades at $17.04, appearing overvalued according to InvestingPro analysis, despite a 21% return over the past year. The news follows Theravance Biopharma's recent agreement to be acquired by Zymeworks Inc. for $929 million and the planned departure of another senior executive.
Form 8K Theravance Biopharma Inc For: 10 September By Investing.com
This article reports on the filing of Form 8K by Theravance Biopharma Inc. on September 10, 2026. The brief notice indicates that the filing pertains to the specified date and includes the company's stock symbol TBPH.
Form 8K Theravance Biopharma Inc For: 10 September By Investing.com
This article reports on a Form 8K filing by Theravance Biopharma Inc. for September 10. The filing is presented without additional commentary or details, indicating a standard corporate disclosure. The article is brief and primarily serves as an announcement of the filing.
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
Theravance Biopharma (TBPH) shares have increased by 0.8% since its last earnings report, outperforming the S&P 500. The company reported Q2 2026 adjusted earnings of 19 cents per share, matching estimates, and total revenues of $20.7 million, slightly exceeding expectations. Theravance's revenue growth was driven by collaboration with Viatris on Yupelri sales and significant cost reductions in R&D and SG&A expenses.
Theravance Biopharma (TBPH) withholds 7,952 insider shares to cover taxes
Theravance Biopharma's SVP, Brett A. Grimaud, had 7,952 Ordinary Shares withheld by the company on August 20, 2026, to satisfy tax obligations related to the vesting of restricted stock units. This transaction, valued at $16.95 per share, was not an open market trade. Following this, Grimaud directly holds 355,168 Ordinary Shares of Theravance Biopharma.
Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trial
Theravance Biopharma announced that its Phase 3 CYPRESS study for ampreloxetine missed its primary endpoint, showing no statistical significance in improving the OHSA composite score. However, post hoc analyses suggested a potential treatment signal in a specific symptomatic patient group, and physiological measures confirmed the drug's biological activity. The FDA has granted a Type C meeting to discuss the design of a potential future pivotal trial for ampreloxetine.
FDA says Theravance (TBPH) needs more data on nOH drug trial
Theravance Biopharma (TBPH) reported that its Phase 3 CYPRESS study for ampreloxetine, a drug for symptomatic neurogenic orthostatic hypotension (nOH), did not meet its primary endpoint. Despite this, post hoc analyses suggested a more coherent treatment effect in a narrowly defined patient population. The FDA has indicated that additional pivotal trials are needed for approval, and Theravance is seeking further guidance on future study design.
Theravance Biopharma (TBPH) CEO logs 20K-share tax withholding
Theravance Biopharma's CEO, Rick E. Winningham, had 20,034 Ordinary Shares withheld on August 20, 2026, at $16.95 per share to cover tax obligations from vested restricted stock units. This transaction was directly with the issuer and not an open market trade. Following this, Winningham directly holds 1,611,022 Ordinary Shares, with additional indirect holdings.
Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH
This article provides a revenue breakdown for Theravance Biopharma, Inc. (NASDAQ:TBPH). The company generated $107.46 million USD in revenue last year, primarily from its Human Therapeutics segment. The United States was the largest contributor to this revenue.
Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. announced its second quarter 2026 financial results, highlighted by strong revenue performance and a detailed corporate update. The report covers key financial metrics and strategic developments for the company.
Theravance Biopharma Deal Faces Investor Probe
Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's board fulfilled its fiduciary duties. Theravance maintains that the deal offers significant value, representing a premium over its stock price before the acquisition announcement.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price, conducted a fair sales process, and disclosed all material information to shareholders. Halper Sadeh LLC may seek increased consideration or other relief on behalf of investors.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC is investigating the sale of Theravance Biopharma, Inc. (TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price for shareholders, ensure a fair sales process, and disclose all material information. Halper Sadeh LLC aims to seek increased consideration or other relief for shareholders.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best price for shareholders, conduct a fair sales process, and disclose all material information. The firm encourages Theravance shareholders to contact them to discuss their rights and options.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The firm is examining whether Theravance and its board of directors violated federal securities laws or breached their fiduciary duties by failing to secure the best possible price for shareholders, conduct a fair sales process, or disclose all material information related to the transaction. Halper Sadeh LLC represents investors globally who have been victims of securities fraud and corporate misconduct.
Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH
Wedge Capital Management L L P NC recently acquired 128,845 shares of Theravance Biopharma (NASDAQ:TBPH) worth approximately $2.19 million, now owning about 0.25% of the company. Institutional investors hold 99.10% of TBPH, despite the company reporting an adjusted loss and missing revenue expectations in its latest quarterly earnings. Analyst ratings for Theravance Biopharma are mostly "Hold," with a consensus price target of $19.40, while insiders have sold a significant number of shares recently.
Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A
Newtyn Management, LLC has disclosed a 6.7% beneficial ownership in Theravance Biopharma (TBPH) through an amended Schedule 13G filing. While Newtyn TE Partners, LP, a part of Newtyn Management, has reduced its holdings to below the 5% reporting threshold, Newtyn Management itself remains above this level. The ownership is based on 51,553,005 Ordinary Shares outstanding as of April 30, 2026.
Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake
An investor group led by Madison Avenue International LP has reported a 17.7% beneficial stake in Theravance Biopharma, Inc. (TBPH) as of June 30, 2026. This ownership, comprising 9,212,252 Ordinary Shares, is based on 51,918,754 outstanding shares as of July 31, 2026. The group, including Madison Avenue Partners, EMAI Management, Madison Avenue GP, Caraway Jackson Investments LLC, and Eli Samaha, collectively holds shared voting and dispositive power over these shares.
Theravance Biopharma (TBPH) Stock Caught Between Fading Gains And Royalty Doubts
Theravance Biopharma (TBPH) reported a significant shift from profit to loss in Q2 2026, with revenue declining by 20.9% year-over-year. The company's earnings per share also moved into negative territory, raising doubts about its reliance on lumpy royalty income and past one-off gains. Both bullish and bearish perspectives highlight the stock's struggle to transition to a steady royalty and orphan drug model, with the market reaction indicating little change in its core thesis.
Theravance Biopharma, Inc. 2026: Revenue $20.73M, EPS ($0.11) — 10-Q Summary
Theravance Biopharma, Inc. (TBPH) reported its 2026 quarterly results, showing a significant decrease in revenue and a net loss compared to the prior year. Revenue dropped by 20.9% to $20.73M, resulting in a diluted EPS of ($0.11) versus $1.08 previously, largely due to the failure of the ampreloxetine Phase 3 trial and subsequent restructuring. The company is undergoing a strategic shift with a merger agreement with Zymeworks and a significant reduction in operating expenses.
Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH
Renaissance Technologies LLC has acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH), purchasing 127,916 shares valued at approximately $2.076 million. This makes Renaissance Technologies LLC one of many institutional investors with holdings in TBPH, as they collectively own 99.10% of the company's stock. Despite the institutional interest, company insiders have sold over 350,000 shares worth $6.0 million in the past quarter, and analysts generally rate the stock as a "Hold" with a consensus price target of $19.40.
Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. (TBPH) reported its second quarter 2026 financial results, highlighting a significant 15% increase in total revenue year-over-year, reaching $40 million. The company's net loss decreased by 10% to $18 million, or $0.30 per share, demonstrating improved financial performance. Key updates included advancements in its pipeline, particularly with izokibep, and a reiteration of its full-year 2026 financial guidance.
Theravance Biopharma Releases Q2 2026 Financial Results
Theravance Biopharma, Inc. (TBPH) reported mixed financial results for Q2 2026, with non-GAAP EPS of $0.11 and revenue of $20.7 million, down 20.9% year-over-year. Despite the revenue decline, the company achieved profitability with a net income of $9.5 million. The revenue was primarily driven by its key product, YUPELRI, which generated $20.7 million, an 11.0% increase from the previous year.
Theravance Biopharma Releases Q2 2026 Financial Results
Theravance Biopharma (TBPH) reported mixed financial results for Q2 2026, with non-GAAP earnings per share of $0.11 and a net income of $9.5M, despite a 20.9% decline in revenue to $20.7M year-over-year. The company's key product, YUPELRI, generated $20.7M in revenue, showing 11.0% year-over-year growth. Wall Street analysts hold diverse views, with consensus at 4 buy and 5 hold ratings for the biopharmaceutical company.
Form 8K Theravance Biopharma Inc For: 10 August By Investing.com
This article reports on the filing of a Form 8K by Theravance Biopharma Inc. for August 10. The short piece from Investing.com provides no further details beyond the title and company information.
Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY
Theravance Biopharma reported a Q2 GAAP net loss of USD 5.9 million, a swing from a profit in the prior year, despite an 11% increase in revenue to USD 20.7 million, primarily from the Viatris collaboration. The company also saw reduced R&D and SG&A expenses, though it incurred transaction-related costs for the Zymeworks acquisition and restructuring expenses. The acquisition by Zymeworks for USD 17 per share plus a CVR is expected to close in the second half of 2026.
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings per share of $0.07, matching analysts' consensus estimates. The company showed a strong return on equity of 18.84% and a net margin of 104.34%. Analysts currently maintain a "Hold" rating on the stock with a consensus price target of $19.40, while insider selling activity and institutional ownership details were also highlighted.
Is Theravance Biopharma Inc (TBPH) Undervalued After Q2 Earnings
Theravance Biopharma Inc (TBPH) released its Q2 2026 earnings, reporting an 11% increase in YUPELRI collaboration revenue to $20.7 million and a 35% reduction in operating expenses. Despite these gains and a solid cash balance, the company faces challenges, including a failed Phase 3 clinical study for ampreloxetine and uncertainties surrounding its acquisition by Zymeworks. GuruFocus values TBPH as undervalued at $24.1 compared to its current price of $16.93, suggesting an attractive entry point for value investors, though caution is advised due to insider selling and low predictability.
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q2 Revenue $20.7M, vs. FactSet Est of $22.5M
Theravance Biopharma, Inc. (TBPH) announced its Q2 revenue of $20.7 million, falling short of FactSet's estimate of $22.5 million. The company's stock was trading at 16.90 USD, reflecting a slight dip in performance. Theravance Biopharma specializes in developing and commercializing medicines for respiratory and neurologic diseases, with key products like YUPELRI for COPD and Ampreloxetine in development for neurogenic orthostatic hypotension.
